CHAMPIONS ONCOLOGY, INC. Royalty Expense
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Royalty Expense of $226.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. royalty expense for the quarter ending 2013-04-30 was 0.00 CAD.
CAD
| Period end | Royalty Expense 3 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|
| 2013-04-30 | 0.00 CAD derived: 10-Q 12 month − 10-Q 9 month · filed 2014-03-14 | 10.00K CAD 10-Q · filed 2014-03-14 | |
| 2013-01-31 | 10.00K CAD 10-Q · filed 2013-03-13 |
USD
| Period end | Royalty Expense 3 month | Royalty Expense 3 month as first filed | Royalty Expense 6 month | Royalty Expense 6 month as first filed | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-07-31 | $226.00K 10-Q · filed 2026-09-11 | $448.00K derived: sum of 2 quarters · filed 2026-09-11 | $647.00K derived: sum of 3 quarters · filed 2026-09-11 | $781.00K derived: sum of 4 quarters · filed 2026-09-11 | ||
| 2026-04-30 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $421.00K derived: sum of 2 quarters · filed 2026-07-27 | $555.00K derived: sum of 3 quarters · filed 2026-07-27 | $594.00K 10-K · filed 2026-07-27 | ||
| 2026-01-31 | $199.00K 10-Q · filed 2026-03-12 | $333.00K derived: sum of 2 quarters · filed 2026-03-12 | $372.00K 10-Q · filed 2026-03-12 | $532.00K derived: sum of 4 quarters · filed 2026-09-11 | ||
| 2025-10-31 | $134.00K 10-Q · filed 2025-12-15 | $173.00K 10-Q · filed 2025-12-15 | $333.00K derived: sum of 3 quarters · filed 2026-09-11 | $450.00K derived: sum of 4 quarters · filed 2026-09-11 | ||
| 2025-07-31 | $39.00K 10-Q · filed 2026-09-11 | $199.00K derived: sum of 2 quarters · filed 2026-09-11 | $316.00K derived: sum of 3 quarters · filed 2026-09-11 | $420.00K derived: sum of 4 quarters · filed 2026-09-11 | ||
| 2025-04-30 | $160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $277.00K derived: sum of 2 quarters · filed 2026-07-27 | $381.00K derived: sum of 3 quarters · filed 2026-07-27 | $462.00K 10-K · filed 2026-07-27 | ||
| 2025-01-31 | $117.00K 10-Q · filed 2026-03-12 | $221.00K derived: sum of 2 quarters · filed 2026-03-12 | $302.00K 10-Q · filed 2026-03-12 | $424.00K derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2024-10-31 | $104.00K 10-Q · filed 2025-12-15 | $185.00K 10-Q · filed 2025-12-15 | $307.00K derived: sum of 3 quarters · filed 2025-12-15 | $421.00K derived: sum of 4 quarters · filed 2025-12-15 | ||
| 2024-07-31 | $81.00K 10-Q · filed 2025-09-15 | $203.00K derived: sum of 2 quarters · filed 2025-09-15 | $317.00K derived: sum of 3 quarters · filed 2025-09-15 | $370.20K derived: sum of 4 quarters · filed 2025-09-15 | ||
| 2024-04-30 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $236.00K derived: sum of 2 quarters · filed 2025-07-23 | $289.20K derived: sum of 3 quarters · filed 2025-07-23 | $362.00K 10-K · filed 2025-07-23 | ||
| 2024-01-31 | $114.00K 10-Q · filed 2025-03-17 | $167.20K derived: sum of 2 quarters · filed 2025-03-17 | $240.00K 10-Q · filed 2025-03-17 | $323.20K derived: sum of 4 quarters · filed 2025-03-17 | ||
| 2023-10-31 | $53.20K 10-Q · filed 2024-12-16 | $126.20K 10-Q · filed 2024-12-16 | $209.20K derived: sum of 3 quarters · filed 2024-12-16 | $230.20K derived: sum of 4 quarters · filed 2024-12-16 | ||
| 2023-07-31 | $73.00K 10-Q · filed 2024-09-13 | $156.00K derived: sum of 2 quarters · filed 2024-09-13 | $177.00K derived: sum of 3 quarters · filed 2024-09-13 | $209.00K derived: sum of 4 quarters · filed 2024-09-13 | ||
| 2023-04-30 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-19 | $104.00K derived: sum of 2 quarters · filed 2024-07-19 | $136.00K derived: sum of 3 quarters · filed 2024-07-19 | $212.00K 10-K · filed 2024-07-19 | ||
| 2023-01-31 | $21.00K 10-Q · filed 2024-03-15 | $53.00K derived: sum of 2 quarters · filed 2024-03-15 | $129.00K 10-Q · filed 2024-03-15 | $244.00K derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-10-31 | $32.00K 10-Q · filed 2023-12-13 | $108.00K 10-Q · filed 2023-12-13 | $223.00K derived: sum of 3 quarters · filed 2023-12-13 | $310.00K derived: sum of 4 quarters · filed 2023-12-13 | ||
| 2022-07-31 | $76.00K 10-Q · filed 2023-09-13 | $191.00K derived: sum of 2 quarters · filed 2023-09-13 | $278.00K derived: sum of 3 quarters · filed 2023-09-13 | $425.00K derived: sum of 4 quarters · filed 2023-09-13 | ||
| 2022-04-30 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-24 | $202.00K derived: sum of 2 quarters · filed 2023-07-24 | $349.00K derived: sum of 3 quarters · filed 2023-07-24 | $401.00K 10-K · filed 2023-07-24 | ||
| 2022-01-31 | $87.00K 10-Q · filed 2023-03-16 | $234.00K derived: sum of 2 quarters · filed 2023-03-16 | $286.00K 10-Q · filed 2023-03-16 | |||
| 2021-10-31 | $147.00K 10-Q · filed 2022-12-13 | $50.00K 10-Q · filed 2021-12-13 | $199.00K 10-Q · filed 2022-12-13 | $194.00K 10-Q · filed 2021-12-13 | ||
| 2021-07-31 | $44.00K 10-Q · filed 2022-09-12 | |||||
| 2021-04-30 | $127.00K 10-K · filed 2022-07-22 | |||||
| 2021-01-31 | $32.00K 10-Q · filed 2022-03-15 | $44.00K derived: sum of 2 quarters · filed 2022-03-15 | ||||
| 2020-10-31 | $12.00K 10-Q · filed 2021-12-13 | |||||
| 2020-04-30 | $128.00K 10-K · filed 2021-07-26 | |||||
| 2012-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-12-13 | $10.00K 10-Q · filed 2012-12-13 | ||||
| 2012-07-31 | $10.00K 10-Q · filed 2012-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |